Lately, MEK inhibitors that inhibit this pathway have been approved to be effective in the reduction in tumor bulk and for improvement in symptoms in cases of inoperable plexiform neurofibromas [1,16]. This evidence concerns the gene MAP2K7 and plexiform neurofibroma.